SEC-sourced researchBeta

REGN

REGENERON PHARMACEUTICALS, INC.

US markets

Data passport

CIK: 0000872589
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Sep 30, 2026
SEC registry record: Operating company

Last updated: Oct 6, 2026, 6:01 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

REGN · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	13,117,200,000.0000	Feb 4, 2026
December 2024	14,202,000,000.0000	Feb 4, 2026
December 2025	14,342,900,000.0000	Feb 4, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	14,342,900,000.0000	4,504,900,000.0000	4,978,900,000.0000	40,558,700,000.0000	9,301,800,000.0000	Feb 4, 2026
December 2024	14,202,000,000.0000	4,412,600,000.0000	4,420,500,000.0000	37,759,400,000.0000	8,405,800,000.0000	Feb 4, 2026
December 2023	13,117,200,000.0000	3,953,600,000.0000	4,594,000,000.0000	—	—	Feb 4, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$14.34B	December 2025	Feb 4, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$14.2B	December 2024	Feb 4, 2026	10-K
Net incomeNetIncomeLoss	$4.5B	December 2025	Feb 4, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	$4.98B	December 2025	Feb 4, 2026	10-K
Total assetsAssets	$40.56B	December 2025	Feb 4, 2026	10-K
Total liabilitiesLiabilities	$9.3B	December 2025	Feb 4, 2026	10-K

New filings

Explore methodology ↗